• Vaccine Name: Brucella abortus strain B19 phenol-insoluble fraction subunit vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009042
• Type: Subunit vaccine
• Status: Research
• Host Species as Laboratory Animal Model: professionally exposed human subjects
• Antigen: phenol-insoluble fraction
• Preparation: Vaccine composed of the phenol-insoluble fraction of Brucella abortus biotype 1 (B19 strain). (Strady et al, 1992)
• Description: This prospective phase IV study involved vaccination of professionally exposed subjects who were negative to an intradermal test for previous contamination. Efficacy: Clinical effectiveness could not be accurately evaluated due to insufficient subject numbers; seropositivity reached 80% after primary vaccination but decreased after 18 months. Immune response: Booster injections restored seropositivity with a thymo-independent type response; no detectable hypersensitivity was observed; local pain occurred after 45.2% of injections and moderate systemic reactions after 5%. (Strady et al, 1992)

Human Response

• Vaccination Protocol: Of 182 subjects screening negative on an intradermal exposure test, 161 accepted vaccination; booster injections were administered at 18 and 36 months. (Strady et al, 1992)
• Immune Response: Booster injections restored seropositivity with a thymo-independent type response; no detectable hypersensitivity was observed; local pain occurred after 45.2% of injections and moderate systemic reactions after 5%. (Strady et al, 1992)
• Efficacy: Clinical effectiveness could not be accurately evaluated due to insufficient subject numbers; seropositivity reached 80% after primary vaccination but decreased after 18 months. (Strady et al, 1992)
• Description: Vaccination of 161 subjects with booster injections at 18 and 36 months; monitoring of local and systemic reactions, seropositivity rates, and hypersensitivity. (Strady et al, 1992)